Background -Drug deposited within the upper airways ofpatients using dry powder inhalers does not contribute to the therapeutic effect but can result in unwanted local side effects and, when swallowed, may contribute to systemic effects. A chamber has been devised which uses the centrifugal force generated by the Turbohaler to remove large "non-respirable" particles with a view to minimising de- "respirable dose". The particle size distribution obtained using the Turbohaler (n = 10) was compared with that from the Turbohaler + chamber (n = 11). Results -The addition of the chamber resulted in the mean (SD) dose contained in larger "non-respirable" particles depositing on stages 1 + 2 being reduced from 52 2 (12.3) to 29-6 (6-9) ig per actuation. However, the chamber did not affect the "respirable" dose. The dose contained in particles with a diameter of <6.8 jim from the standard Turbohaler was 91-1 (8.9) ig compared with 82-4 (18-6) jg when used with the chamber. Conclusions -These results indicate that it is possible to devise an effective particle size selection device for the Turbohaler. It may be possible to produce such devices for other dry powder inhalers, although the design would need to be tailored to each particular device.
Abstract
Background -Drug deposited within the upper airways ofpatients using dry powder inhalers does not contribute to the therapeutic effect but can result in unwanted local side effects and, when swallowed, may contribute to systemic effects. A chamber has been devised which uses the centrifugal force generated by the Turbohaler to remove large "non-respirable" particles with a view to minimising de- Dry powder inhalers are widely used for generating aerosols for the treatment of asthma. Current devices utilise energy provided by the inspiratory effort of the patient to disaggregate the micronised particles. The greater the inspiratory effort, the more effective the disaggregation and the greater the "respirable dose". The improved disaggregation that occurs as inspiratory flows increase more than offsets the increased loss of particles in the upper airways due to the higher velocity and results in improved drug delivery to the lungs. 8 However, even when current dry powder inhalers are used optimally, it is inevitable that a substantial portion of the dose deposits in the upper airways.7-9 For bronchodilators this is of little consequence, but for steroids this dose may contribute significantly to both systemic and local side effects.
Spacers and holding chambers are widely used when steroids are delivered via metered dose inhalers in order to reduce the oral pharyngeal dose and so minimise the potential for unwanted side effects. No such device is currently available for dry powder inhalers and therefore a chamber was devised which utilises the centrifugal force generated by the Turbohaler to remove large "non-respirable" particles. The effectiveness of the chamber was determined in vitro using a multistage liquid impinger.
Methods
As we were unable to manufacture our own chamber, we modified an existing small volume spacer, the ACE chamber (DHD, Canastota, USA), designed for use with metered dose inhalers. This chamber has the general shape we desired but is rather larger than we would have chosen. The chamber and the mouthpiece of a Turbohaler were modified to permit the chamber to be attached to it (figure). Modification of the Turbohaler involved cutting back the mouthpiece to reveal the insert containing the spiral channels; this was then enclosed in a rubber sleeve which could be inserted into the tapered end of the chamber. The chamber was modified by removing the port used for actuating the metered dose inhaler.
An Astra multistage liquid impinger (Copley, Nottingham, UK) was used to assess the total dose and particle size distribution of the aerosol delivered by a 200 1tg budesonide Turbohaler with (n = I 1) and without (n = 1 0) the cham- 
Discussion
Results from this study suggest that a substantial reduction in the coarse "non-respirable" fraction of an aerosol generated by the Turbohaler can be achieved by using a simple, appropriately designed chamber. The dose contained in fine "respirable" particles was unaffected, which suggests that a chamber such as this one might significantly reduce the dose depositing in the upper airway without reducing the dose to the lungs.
Disaggregation of the micronised powder delivered from a Turbohaler is enhanced by passage ofpowder through the spiral mouthpiece.' The spheronised powder is abraded as it is forced over the outer surface of the spiral. As the particles leave the mouthpiece they retain both forward and centrifugal momentum, and hence tend to spiral outwards as they leave the mouthpiece. The chamber operates as a size selection device by initially allowing the plume of powder to expand. The particles are then required to change direction in order to escape via the mouthpiece. The larger particles impact because of their greater inertia, while smaller particles are entrained by the airflow through the mouthpiece and are available to the patient.
Aerosol exiting the chamber will have lost the initial centrifugal momentum and this may further reduce oral deposition by reducing drug deposition resulting from particles impacting on, and adhering to, the moist mucous membranes ofthe mouth as a result of their tendency to spiral outwards. It is probable that some fine particles which would normally pass straight through the upper airway at a given inspiratory flow are lost in this manner.
These studies were performed using a flow rate of 60 1/min. It is likely that such a device will be less efficient at lower rates because of the lower velocity of particles, although the exact effect is unpredictable as there will be more large particles with high inertia. It is noticeable that the variability in the dose that is deposited on stages 3 + 4 when using the chamber is considerably greater than for the standard device alone. This may be the result of the variable static charge carried by the chamber as has been described for holding chambers,"' and this potential problem would need to be addressed if such a chamber were to be used therapeutically.
The ACE chamber was used because it was available. Analysis of slow motion video film of Turbohalers being actuated suggests that a smaller chamber with a slightly different design might be more efficient at removing "nonrespirable" particles. Hence, further work is required to define the optimal size and design for such a particle selective device. However, these results show that it is possible to develop simple effective particle size selection devices for at least some dry powder inhalers.
Background -Clinical and laboratory features do not accurately correlate with the cause of community acquired pneumonia. A study was performed to examine whether the radiographic features of staphylococcal pneumonia are sufficiently distinct to aid early diagnosis. Methods -The chest radiographs of 34 patients (including eight children) with proven staphylococcal pneumonia were reviewed by two experienced observers using methods described previously. 
